Aura Biosciences is a Boston-based company focused on the development of drugs using tumor targeted pseudovirions, synthetic viruses that demonstrate key targeting selectivity for solid tumors and metastases and can efficiently release target molecules within cancerous cells.

The company’s lead product is focused on treating life-threatening ocular cancers for which no FDA-approved therapies are available. By applying its novel viral nanoparticle technology, developed in partnership with the National Cancer Institute (NCI), Aura is dedicated to bringing this patient population first-in-class therapies that can both eliminate the tumor and preserve vision.